Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012-2015

References

• Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–854. doi:10.1086/43280316107985
   PubMed Web of Science ®Google Scholar
• Riley LW. Pandemic lineages of extraintestinal pathogenic Escherichia coli. Clin Microbiol Infect. 2014;20:380–390. doi:10.1111/1469-0691.1264624766445
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166. doi:10.1016/S1473-3099(08)70041-018291338
   PubMed Web of Science ®Google Scholar
• Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–67. doi:10.1093/cid/cir20221653305
   PubMed Web of Science ®Google Scholar
• Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gram-negative bacteria. Annu Rev Microbiol. 2011;65:455–478. doi:10.1146/annurev-micro-090110-10291121740228
   PubMed Web of Science ®Google Scholar
• Iovleva A. Carbapenem-resistant Enterobacteriaceae. Clin Lab Med. 2017;37:303–315.28457352
   PubMed Web of Science ®Google Scholar
• Guh AY, Bulens SN, Mu Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA. 2015;314:1479–1487. doi:10.1001/jama.2015.1248026436831
   PubMed Web of Science ®Google Scholar
• Jeong SH, Kim HS, Kim JS, et al. Prevalence and molecular characteristics of carbapenemase-producing Enterobacteriaceae from five hospitals in Korea. Ann Lab Med. 2016;36:529–535. doi:10.3343/alm.2016.36.6.52927578505
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Lob SH, Kazmierczak KM, et al. In vitro activity of imipenem against carbapenemase-positive Enterobacteriaceae isolates collected by the SMART Global Surveillance Program from 2008 to 2014. J Clin Microbiol. 2017;55:1638–1649. doi:10.1128/JCM.02316-1628298454
   PubMed Web of Science ®Google Scholar
• Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum beta-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–326.20614578
   PubMed Web of Science ®Google Scholar
• Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28:565–591. doi:10.1128/CMR.00116-1425926236
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 27th ed. Vol. Supplement M100 Wayne (PA): CLSI; 2017.
   Google Scholar
• Chiu SK, Wu TL, Chuang YC, et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One. 2013;8:e69428. doi:10.1371/journal.pone.006942823894478
   PubMed Web of Science ®Google Scholar
• Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother. 2004;48:533–537. doi:10.1128/aac.48.2.533-537.200414742206
   PubMed Web of Science ®Google Scholar
• Eckert C, Gautier V, Saladin-Allard M, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004;48:1249–1255. doi:10.1128/aac.48.4.1249-1255.200415047527
   PubMed Web of Science ®Google Scholar
• D’Agata EM, Gerrits MM, Tang YW, Samore M, Kusters JG. Comparison of pulsed-field gel electrophoresis and amplified fragment-length polymorphism for epidemiological investigations of common nosocomial pathogens. Infect Control Hosp Epidemiol. 2001;22:550–554. doi:10.1086/50195011732783
   PubMed Web of Science ®Google Scholar
• Freire P, Vieira HL, Furtado AR, et al. Effect of the morphogene bolA on the permeability of the Escherichia coli outer membrane. FEMS Microbiol Lett. 2006;260:06–111. doi:10.1111/j.1574-6968.2006.00307.x
   Web of Science ®Google Scholar
• Wirth T, Falush D, Lan R, et al. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol. 2006;60:1136–1151. doi:10.1111/j.1365-2958.2006.05172.x16689791
   PubMed Web of Science ®Google Scholar
• Ma L, Siu LK, Lin JC, et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infect Dis. 2013;13:599. doi:10.1186/1471-2334-13-59924354657
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17:1135–1141. doi:10.1111/j.1469-0691.2011.03553.x21635663
   PubMed Web of Science ®Google Scholar
• Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–163. doi:10.1016/S1473-3099(16)30257-227866944
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018;62:e01882–17.29203488
   PubMed Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e00642-17. doi:10.1128/AAC.00642-17
   Web of Science ®Google Scholar
• Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, et al. Treatment of infections caused by Extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:e00079-17.
   Web of Science ®Google Scholar
• Chiu SK, Ma L, Chan MC, et al. Carbapenem nonsusceptible Klebsiella pneumoniae in Taiwan: dissemination and increasing resistance of carbapenemase producers during 2012-2015. Sci Rep. 2018;8:8468. doi:10.1038/s41598-018-26691-z29855588
   PubMed Web of Science ®Google Scholar
• Chang YT, Coombs G, Ling T, et al. Epidemiology and trends in the antibiotic susceptibilities of Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region, 2010-2013. Int J Antimicrob Agents. 2017;49:734–739. doi:10.1016/j.ijantimicag.2017.01.03028435019
   PubMed Web of Science ®Google Scholar
• Jean SS, Coombs G, Ling T, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013. Int J Antimicrob Agents. 2016;47:328–334. doi:10.1016/j.ijantimicag.2016.01.00827005459
   PubMed Web of Science ®Google Scholar
• Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents. 2017;50:127–134. doi:10.1016/j.ijantimicag.2017.03.01228647532
   PubMed Web of Science ®Google Scholar
• Gomez-Simmonds A, Nelson B, Eiras DP, et al. Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2016;60:3601–3607. doi:10.1128/AAC.03007-1527044555
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–734. doi:10.1016/S1473-3099(17)30228-128442293
   PubMed Web of Science ®Google Scholar